Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FXS5626 adaptive seamless phase II/III trial in nonsegmental vitiligo
CTR20263504Phase 3Active
- Sponsor
- Fosun Pharma
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of FXS5626 in nonsegmental vitiligo, sponsored by Fosun Pharma. Started Sep 2026; status: active.
02
Drugs
FXS5626
03
Conditions
nonsegmental vitiligo
Beyond the preview
Go deeper on CTR20263504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263504.